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Abstract: Chemoresistance is mediated, in part, by the inhibition 
of apoptosis in tumor cells. Survivin is an antiapoptotic protein that 
blocks chemotherapy-induced apoptosis. To investigate whether 
blocking survivin expression enhances docetaxel-induced apopto-
sis in patients with non–small-cell lung cancer (NSCLC), we com-
pared the antitumor activity of the survivin inhibitor LY2181308 
plus docetaxel with docetaxel alone. We used change in tumor size 
(CTS) as a primary endpoint to assess its use in early decision-making 
for this and future studies of novel agents in NSCLC. Patients (N = 
162) eligible for second-line NSCLC treatment (stage IIIB/IV) with 
an Eastern Cooperative Oncology Group performance status of 0 to 
1 were randomized 2:1 to receive LY2181308 (750 mg intravenously, 
weekly) and docetaxel (75 mg/m2 intravenously, day 1) or docetaxel 
alone every 21 days. CTS from baseline to the end of cycle 2 was 
compared between the two treatment arms. The mean (SD) tumor size 
ratio for LY2181308/docetaxel and docetaxel was 1.05 (0.21) and 1.00 
(0.15) (p = 0.200), respectively, suggesting no significant improvement 
in antitumor activity between the arms. Because there was also no sig-
nificant difference between the two arms for progression-free survival 
(PFS) (2.83 months with LY2181308/docetaxel and 3.35 months with 
docetaxel [p = 0.191]), both arms were combined. Using the combined 
arms, CTS correlated with PFS (PFS = 4.63 months in patients with 
decreased CTS compared with 2.66 months in patients with increased 
CTS), supporting its use in early decision-making in phase II studies.
Key Words: Change in tumor size, Non–small-cell lung cancer, 
Docetaxel, Survivin, LY2181308
(J Thorac Oncol. 2014;9: 1704–1708)
Lung cancer is one of the most common malignancies worldwide, and is the leading cause of cancer death in 
most countries.1 Currently, patients with advanced or meta-
static non–small-cell lung cancer (NSCLC) who fail first-line 
treatment have several treatment options, including docetaxel, 
which has a median overall survival (OS) of 7.9 months and a 
median progression-free survival (PFS) of 2.9 months.2 This 
limited response to second-line treatment results from chemo-
resistance associated with the inhibition of apoptosis.3 One 
protein implicated in chemoresistance and failure to undergo 
apoptosis is the antiapoptotic protein, survivin.4
In preclinical models, the survivin inhibitor, LY2181308, 
a second-generation antisense oligonucleotide, showed enhanced 
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antitumor activity when combined with docetaxel.5 These 
observations led to the clinical evaluation of a combination of 
LY2181308 and docetaxel in cancer patients.6 It was hypothesized 
that blocking the expression of survivin with LY2181308 would 
restore default cell-death checkpoints and selectively eliminate 
cancer cells, leading to improved outcomes for NSCLC patients.5
To investigate the hypothesis that the combination of 
LY2181308 plus docetaxel is safe and potentially efficacious, 
we designed an open-label, randomized phase II study of sec-
ond-line treatment in patients with NSCLC. Based on a previ-
ous publication,7 the primary endpoint in this trial was change in 
tumor size (CTS) from baseline assessed at the end of cycle 2.
PATIENTS AND METHODS
Patients
Patients were at least 18 years of age and had a histologi-
cal diagnosis of NSCLC (stage IIIB or IV at entry) that had pro-
gressed after one line of systemic chemotherapy. This study was 
conducted in accordance with the ethical principles originating 
in the Declaration of Helsinki, good clinical practice, and all 
applicable laws and regulations. The ethical review board at 
each site approved the study, and all patients provided written 
informed consent before undergoing any study procedure.
Treatment and Study Design
Patients were randomized in a 2:1 ratio to the experimen-
tal combination (LY2181308 and docetaxel arm) or standard-
of-care treatment (docetaxel arm). Before cycle 1, patients in 
the LY2181308/docetaxel arm received two consecutive load-
ing doses of 750 mg LY2181308 intravenously for 3 hours each 
one and two days prior to day 1 of cycle 1.8 A third loading dose 
was administered on day 1 of cycle 1, followed by weekly main-
tenance doses (on days 6 and 14) of 750 mg LY2181308. On 
day 1 of cycle 1, patients received 75 mg/m2 docetaxel (admin-
istered over approximately 1 hour) 1 hour after LY2181308 
infusion. Beginning with cycle 2 (and beyond), LY2181308 
was administered on days 1, 8, and 15, with docetaxel 75 mg/
m2 on day 1 of each cycle until disease progression. Each cycle 
started with the administration of docetaxel and lasted 21 days 
(see Supplementary Fig. 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A645 for study diagram).
The primary objective was to evaluate the antitumor 
activity of LY2181308 in combination with docetaxel using 
CTS from baseline to the end of cycle 2 as an endpoint, as 
proposed by Karrison et al.9 The approach of using tumor size 
measurements as a continuous rather than categorical variable 
for assessing antitumor activity preserves information at the 
patient level and increases statistical efficiency as suggested 
by Lavin et al.10 Secondary objectives included a comparison 
of the following between treatment arms: PFS, OS, objective 
response rate, safety, pharmacokinetic profiles, and tumor 
markers associated with tumor progression, such as plasma 
CK19 fragment (CYFRA21-1) and carcinoembryonic antigen.
Endpoint Assessments
For the analysis of CTS, tumors were measured per 
Response Evaluation Criteria in Solid Tumors 1.111 using 
serial high-resolution computed tomography imaging. Scans 
of the chest/abdomen/pelvis were performed at baseline and 
at every other cycle. All images were collected at 3-mm slices 
or with higher resolution, read by local investigators and by 
a central assessment (VirtualScopics, Rochester, NY). Safety 
was assessed in every cycle by analyzing adverse events (AEs, 
graded per Common Terminology Criteria for Adverse Events 
v4.0) and serious AEs. CYFRA21-1 and carcinoembryonic 
antigen were measured in plasma at baseline and before each 
cycle at a central laboratory (Quintiles, Durham, NC).
Statistical Analyses
Patients who received at least one dose of study drug 
were included in all statistical analyses. All tests of treatment 
effects were conducted at a two-sided alpha level of 0.05.
The analysis of the primary endpoint (i.e., CTS) was 
planned to occur after 120 patients received at least two 
cycles of therapy. Using simulations, chances of detecting 
a difference in CTS at the 5% significance level with this 
sample size were 100%, 99%, or 86%, if the assumed differ-
ences in CTS were 60%, 50%, and 40%, respectively. CTS, 
analyzed as the log of the ratios of tumor size (defined as 
the sum of the longest diameters) at visit 2 to tumor size 
at baseline, follows a normal distribution and was com-
pared between the treatment arms using a t test. The primary 
analyses were based on the measurements obtained from 
the central imaging assessment. Kaplan–Meier curves were 
produced for each time-to-event variable,12 and the differ-
ences between arms were assessed with the log-rank test. 
The effect of prognostic factors on PFS was assessed using a 
Cox proportional hazards model.13
RESULTS
Patient Disposition
The study was conducted from May 2010 to June 2012. 
A total of 207 patients entered the study, of which 120 were 
randomized to LY2181308/docetaxel and 60 to docetaxel 
TAbLE 1.  Ratio of Tumor Sizea at Cycle 2 to That at Baseline
LY2181308 
and Docetaxel 
(N = 114)
Docetaxel 
(N = 48)
Total  
(N = 162) pb
Investigator-determined (based on case report forms)
  Number of patients 85 36 121 0.666
  Mean (SD) 1.07 (0.28) 1.04 (0.28) 1.06 (0.28)
  Median 1.03 1.00 1.02
  Missing 0 1 1
Central assessment of imaging data
  Number of patients 82 42 124 0.200
  Mean (SD) 1.05 (0.21) 1.00 (0.15) 1.03 (0.19)
  Median 1.02 0.97 1.02
  Missing 0 0 0
aThe sum of lesion diameters is calculated per Response Evaluation Criteria in Solid 
Tumors 1.1 guidelines.
bp value from comparison using t test. The t test is based on the logarithm of the ratio 
of tumor size at cycle 2 to that at baseline, as this measure follows a normal distribution.
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(docetaxel monotherapy) (Supplementary Fig. 2, Supplement 
al Digital Content 2, http://links.lww.com/JTO/A646). Of 
the enrolled patients, 90% (162 of 180) were eligible for the 
study evaluation (especially for CTS assessment). Patient 
demographics were similar between the two arms with respect 
to age, race, sex, and Eastern Cooperative Oncology Group 
performance status (Supplementary Table 1, Supplemental 
Digital Content 3, http://links.lww.com/JTO/A647).
Change in Tumor Size
Based on central imaging data, the mean (SD) tumor 
size ratio at cycle 2 to that at baseline was 1.05 (0.21) with 
LY2181308/docetaxel and 1.00 (0.15) with docetaxel (p = 0.200). 
These data coincided with the investigator-assessed CTS eval-
uation (Table 1) (1.07 [0.28] with LY2181308/docetaxel ver-
sus 1.04 [0.28] with docetaxel; p = 0.666). A waterfall plot for 
CTS was produced for the treatment groups based on the cen-
tral imaging data (Supplementary Fig. 3, Supplemental Digital 
Content 4, http://links.lww.com/JTO/A648). Tumor size 
diameter by visit and treatment is depicted in Supplementary 
Figure 4 (Supplemental Digital Content 5, http://links.lww.
com/JTO/A649).
Progression-Free Survival
The median PFS was 2.83 (95% confidence interval 
[CI], 1.84–3.65) months with LY2181308/docetaxel and 
3.35 (95% CI, 2.69–4.57) months with docetaxel (p = 0.191) 
(Supplementary Table 2, Supplemental Digital Content 3, 
http://links.lww.com/JTO/A647, and Fig. 1A).
As depicted in a forest plot (Fig. 2A), CTS (decrease 
versus increase), age (<65 versus ≥65), and lactate dehydro-
genase (high versus low) were identified as factors affecting 
PFS (Figs. 2B–D). For both arms combined, CTS reduction 
translated to longer PFS (PFS of 4.63 months in patients with 
decreased CTS compared with 2.66 months in patients with 
increased CTS).
In a subgroup of patients (N = 50), CYFRA21-1 levels 
were available.14 Patients with low baseline CYFRA21-1 lev-
els had a median PFS of 5.62 months (95% CI, 2.66–5.91), 
whereas patients with high CYFRA21-1 baseline levels had a 
median PFS of 1.61 months (95% CI, 1.35–2.86).
Overall Survival
The median OS (90% CI) was 7.9 (6.6–9.7) months with 
LY2181308/docetaxel and 8.8 (5.7–13.8) months with docetaxel 
FIgURE 1.  Kaplan–Meier graphs of PFS and OS. A, 
Kaplan–Meier graph for PFS, all treated patients; (B) 
Kaplan–Meier graph for OS, all treated patients. PFS, 
progression-free survival; OS, overall survival.
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(p = 0.481) (Supplemental Table 2, Supplemental Digital 
Content 3, http://links.lww.com/JTO/A647, and Fig. 1B).
Tumor Response
Partial response was observed in seven patients in the 
LY2181308/docetaxel arm and one patient in the docetaxel 
arm, yielding objective response rates (95% CI) of 6.1% 
(1.7%–10.5%) and 2.1% (2.0%–6.1%), respectively (p = 
0.438) (Supplemental Table 2, Supplemental Digital Content 
3, http://links.lww.com/JTO/A647).
Safety
Ten (8.8%) patients in the LY2181308/docetaxel arm 
and three (6.3%) patients in the docetaxel arm discontinued 
FIgURE 2.  Evaluation of influence factors on PFS. A, Influence of various baseline and prognostic factors on PFS, patients on 
therapy; (B) Kaplan–Meier graph for PFS by CTS at visit 2 split at median, patients on therapy; (C) Kaplan–Meier graph for PFS 
by age group, patients on therapy; (D) Kaplan–Meier graph for PFS by LDH split at median, patients on therapy. CTS, change in 
tumor size; ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactate dehydrogenase; PFS, progression-
free survival; IV, intravenous.
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due to serious AEs considered possibly related to study 
drug. The most frequently reported grade 3/4 AEs were sim-
ilar between the two treatment arms (Supplemental Table 
3, Supplemental Digital Content 3, http://links.lww.com/
JTO/A647) and consistent with the known docetaxel toxic-
ity profile.
Pharmacokinetics
Pharmacokinetics of LY2181308 alone, docetaxel alone, 
and docetaxel in combination with LY2181308 were consis-
tent with their respective known profiles (Supplementary Figs. 
5–7, Supplemental Digital Content 6-8, http://links.lww.com/
JTO/A650, http://links.lww.com/JTO/A651, http://links.lww.
com/JTO/A652).
DISCUSSION
Antitumor activity seen in preclinical models5 did not 
translate to clinical benefit in the present randomized phase 
II study comparing LY2181308 and docetaxel with standard 
docetaxel in patients with NSCLC. A similar observation was 
made in patients with prostate cancer.6 There are several pos-
sible reasons for our findings. First, although the dose and 
schedule of LY2181308 used in this study were previously 
shown to reduce survivin,8 tumor tissue was not obtained to 
confirm target inhibition in lung cancer patients in the cur-
rent study. Second, this trial did not select patients on the 
basis of histology or biomarkers of tumor survivin expres-
sion, raising the possibility that benefit in a subset of patients 
was missed. Finally, we cannot exclude that survivin is not a 
dominant mechanism in the development of chemoresistance 
in NSCLC.
CTS was chosen as a primary endpoint to assess antitu-
mor activity because it can serve as an early evaluation of effi-
cacy in phase II studies.9 Although no statistically significant 
difference was observed between treatment arms, CTS did 
emerge as a potentially useful early endpoint across the entire 
study population, with a significant association between CTS 
and PFS. Thus, for future clinical trial designs, CTS appears 
to be an early marker of efficacy, with relatively short time 
intervals, that can aid in monitoring the efficacy of new treat-
ments and hence accelerate decision-making in early-phase 
clinical trials.
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